Voyager Therapeutics, Inc.

NasdaqGS:VYGR

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 164.35 M

Share Price

USD 2.97

Avg Daily Volume

460,479

Change (1 day)

-2.30%

Change (1 year)

-61.87%

Change (YTD)

-47.62%

Voyager Therapeutics, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -47.62%

Voyager Therapeutics, Inc. Share Price Year-To-Date (YTD) return is -47.62% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Voyager Therapeutics, Inc. 52-week low Share Price is USD 9.27 on June 20, 2025, which is 212.12% above the current Share Price.
Voyager Therapeutics, Inc. 52-week low Share Price is USD 2.73 on June 20, 2025, which is -8.08% below the current Share Price.
Voyager Therapeutics, Inc. average Share Price for the last 52 weeks is USD 5.54.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqGS: VYGR

Voyager Therapeutics, Inc.

CEO	Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
IPO Date	Nov. 11, 2015
Location	United States
Headquarters	75 Sidney Street
Employees	172
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.